Mineralys Therapeutics, Inc. (MLYS)
25.59
-0.08
(-0.31%)
USD |
NASDAQ |
Sep 01, 16:00
25.59
0.00 (0.00%)
After-Hours: 17:00
Mineralys Therapeutics Cash from Operations (TTM) : -138.79M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -138.79M |
| March 31, 2026 | -136.40M |
| December 31, 2025 | -142.42M |
| September 30, 2025 | -171.37M |
| June 30, 2025 | -192.68M |
| March 31, 2025 | -192.66M |
| December 31, 2024 | -166.31M |
| September 30, 2024 | -128.45M |
| Date | Value |
|---|---|
| June 30, 2024 | -97.30M |
| March 31, 2024 | -87.54M |
| December 31, 2023 | -81.17M |
| September 30, 2023 | -62.38M |
| June 30, 2023 | -50.34M |
| March 31, 2023 | -35.42M |
| December 31, 2022 | -29.22M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| MapLight Therapeutics, Inc. | -174.67M |
| Evommune, Inc. | -74.15M |
| Arrowhead Pharmaceuticals, Inc. | -59.06M |
| Oncolytics Biotech, Inc. | -26.52M |
| Sangamo Therapeutics, Inc. | -90.34M |